Zentalis Prices $80.5M Public Offering at $3.50/Share
ZNTL has more than doubled off its 52-week low of $1.212 on elevated volume (3.8× avg).
Summary
Zentalis priced a 23 million share public offering at $3.50 per share, raising approximately $75.1 million in net proceeds to fund clinical development and operations.
Key Events · Financing and Capital Events · ZNTL
-
Offering Priced at $3.50/Share
23,000,000 shares priced at $3.50 per share, a 6.6% discount to the last close, with a 30-day option for 3,450,000 additional shares.
-
Net Proceeds of $75.1M
Estimated net proceeds of approximately $75.1 million after underwriting discounts and expenses, extending cash runway into late 2027.
-
Underwriters and Closing
TD Securities, Guggenheim Securities, and Oppenheimer & Co. are joint book-runners; closing expected August 17, 2026.
-
Use of Proceeds
Funds will support clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostic, pre-commercial activities, and working capital.
Analysis · ZNTL · Life Sciences
Zentalis formalized its underwritten public offering of 23 million shares at $3.50 per share, with an option for 3.45 million more. Net proceeds are estimated at $75.1 million, extending the company's cash runway into late 2027. The offering was priced at a 6.6% discount to the prior close, and the stock fell 12% on the news, reflecting dilution concerns. The capital funds ongoing clinical trials for azenosertib, including the Phase 3 ASPENOVA trial, and supports pre-commercial activities.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZNTL was trading at $3.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $255.2M. The 52-week trading range was $1.21 to $6.95. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.